BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma
Abstract
Follicular lymphoma (FL) is characterized by a relatively indolent clinical course, but the disease often transforms into a more aggressive large cell lymphoma with a rapidly progressive clinical course. In the present study, we analyzed 41 cases of FL known to have subsequently transformed to aggressive lymphoma and an additional 64 FL samples from patients not subsequently transformed. We studied BCL6 gene rearrangement by the methodology of long-distance inverse polymerase chain reaction (LDI-PCR). Of the 41 cases known to transform, 16 (39.0%) harbored BCL6 translocation or deletion at the time of FL diagnosis. Among 64 cases not known to transform, BCL6 translocation was detected in 9 (14.1%). The prevalence of BCL6 translocation in the group known to transform was significantly higher (P = .0048). Among the transformation cases, the partners of the BCL6 translocation were identified in 13 cases and included IGH, CIITA, U50HG, MBNL, GRHPR, LRMP, EIF4A2, RhoH/TTF, and LOC92656 (similar to NAPA), whereas in the control group the BCL6 partners were IGH, CIITA, SIAT1, and MBNL. In 13 cases paired specimens before and after transformation were available. Among these paired specimens, a loss (3 cases) or a gain (1 case) of BCL6 translocation was observed after the transformation. Analysis of clonality showed that all of these cases represented the evolution of a subclone of the original tumor population. Our study demonstrated that BCL6 translocation is not necessary for transformation but that BCL6 translocation in FL may constitute a subgroup with a higher risk to transform into aggressive lymphoma.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the transformation from follicular lymphoma to diffuse large B-cell lymphoma, LAZ3/BCL6 translocations with RHOH were widespread.
“The authors found that in the course of transformation from the rather indolent follicular lymphoma into the more aggressive diffuse large B-cell lymphoma, LAZ3/BCL6 translocations with RHOH were widespread.”
From The small GTPase RhoH is an atypical regulator of haematopoietic cells (2008) · cites this paper as [41]
Cited by
Sorted by citations
The small GTPase RhoH is an atypical regulator of haematopoietic cells
Fueller, F., & Kubatzky, K. F. (2008) · Cell Communication and Signaling · doi:10.1186/1478-811x-6-6 · Cited by 40 · see citing works
- Authors
- Akasaka, T., Lossos, I. S., & Levy, R.
- Affiliations
- Stanford Medicine (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2003-08-15
- Volume
- 102
- Issue
- 4
- Pages
- 1443-1448
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2055643760
- Cited by
- 156
- References
- 0
- Citations by year
- 2026: 5 · 2025: 3 · 2023: 8 · 2022: 7 · 2021: 4 · 2020: 8 · 2019: 7 · 2018: 8 · 2017: 8 · 2016: 6 · 2015: 10 · 2014: 5 · 2013: 5 · 2012: 2
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 33399, P01CA034233, CA 34233)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- follicular lymphoma, BCL6 translocation, lymphoma transformation, diffuse large B-cell lymphoma, clonal evolution, immunoglobulin heavy chain, CIITA, risk stratification
- MeSH terms
- Cell Transformation, Neoplastic, Cloning, Molecular, DNA-Binding Proteins, Humans, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Proto-Oncogene Proteins, Transcription Factors, Translocation, Genetic, Gene Rearrangement, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, Disease Progression, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-bcl-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review